The Selling In FibroGen Stock Appears Overdone After Roxadustat Delay

The stock price of FibroGen, a biopharmaceutical company focused on therapeutics in immunology and oncology, has seen a large 36% drop over the last ten trading days, while it's down 32% over the last five trading days, but we believe the stock, after the recent drop, may trend higher in the near...